Lara Longpre - 10 Sep 2019 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
10 Sep 2019
Net transactions value
-$10,417
Form type
4
Filing time
18 Mar 2024, 17:40:14 UTC
Next filing
12 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Purchase $10,268 +965 +0.92% $10.64 105,372 10 Sep 2019 Direct F1
transaction MIRM Common Stock Sale $20,684 -1,003 -0.95% $20.62 104,369 09 Jan 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F2 Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units.